Initial Experience with Standalone Thoracoscopic Left Atrial Appendage Occlusion Using AtriClip Pro2: A Single-Center Retrospective Cohort Study in Latvia
This small, heterogeneous, single-center series supports the technical feasibility of standalone thoracoscopic AtriClip Pro2 implantation in selected patients and warrants further evaluation in larger cohorts with longer clinical follow-up and standardized postoperative imaging.
Abstract
Background and Objectives: Left atrial appendage (LAA) closure is an established strategy for stroke prevention in selected patients with atrial fibrillation (AF), particularly when long-term oral anticoagulation (OAC) is contraindicated. Thoracoscopic epicardial LAA occlusion using the AtriClip Pro2 device provides a minimally invasive surgical approach; however, evidence for standalone use remains limited. This study aimed to describe the initial feasibility and early clinical outcomes of standalone thoracoscopic LAA occlusion using AtriClip Pro2 in Latvia. Materials and Methods: We performed a single-center retrospective observational study including all consecutive patients who underwent standalone thoracoscopic LAA occlusion at the Department of Cardiac Surgery, Pauls Stradins Clinical University Hospital, between December 2024 and March 2026. Baseline characteristics, procedural outcomes, perioperative complications, rehospitalizations, and antithrombotic therapy status were assessed. LAA closure was assessed by transesophageal echocardiography (TEE). Results: Fourteen patients were included. Mean age was 63.6 ± 16.7 years (median 67.0; IQR 54.8–76.8), and 64.3% were female. Thoracoscopic completion was achieved in 13/14 patients (92.9%; 95% CI 68.5–98.7%); one patient (7.1%) required conversion to median sternotomy because of intraoperative bleeding. Complete LAA exclusion without residual flow or stump was documented in all 14 patients (100%; 95% CI 78.5–100%). No perioperative stroke or mortality occurred. At three months, follow-up data were available for all patients, and antithrombotic therapy had been discontinued in 12/14 patients (85.7%). Conclusions: This small, heterogeneous, single-center series supports the technical feasibility of standalone thoracoscopic AtriClip Pro2 implantation in selected patients. These encouraging early findings warrant further evaluation in larger cohorts with longer clinical follow-up and standardized postoperative imaging.
BACKGROUND
Left atrial appendage occlusion (LAAO) reduces thromboembolic risk in patients with atrial fibrillation (AF) who have contraindications to oral anticoagulation (OAC). LAAO can be performed surgically (S-LAAO) or percutaneously (pLAAO), but direct comparative evidence remains limited.
METHODS
We conducted a...
Julian Chestaro, Hannah Price, Joel Matthews et al.· Current problems in cardiolo...· 0 citations
Aim
. To improve the quality of high-tech health care provided to patients with atrial fibrillation (AF) by performing left atrial appendage (LAA) resection with an endoscopic stapler during thoracoscopic isolation of left atrial (LA) arrhythmogenic zones.
Material and methods
. This article presents the surgi...
A. Bagdasaryan, T. Shcherbinin, E. Khomenko et al.· Russian Journal of Cardiolog...· 0 citations
BACKGROUND
Surgical closure of the left atrial appendage (LAA) reduces stroke risk in patients with atrial fibrillation (AF) undergoing cardiac surgery. We evaluated the safety and efficacy of prophylactic LAA closure during bioprosthetic surgical aortic valve replacement in patients without prior AF.
METHODS
In this...
Tuomas O. Kiviniemi, F. Halfwerk, Juan Bustamante Munguira et al.· Journal of the American Hear...· 0 citations
Extending the CT stroke protocol to the LAA was technically feasible and did not significantly increase radiation dose, but added little diagnostic yield, and on current evidence should complement rather than replace echocardiography.
Kaitlyn E. Heintzelman, Enrique M. Carrera, Katherine Burkhardt et al.· Hearts· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.